Challenge Grants: Biodefense and Sars Product Development
The summary for the Challenge Grants: Biodefense and Sars Product Development grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Challenge Grants: Biodefense and Sars Product Development: Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, strives to understand, treat and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten millions of human lives. The NIAID Division of Microbiology and Infectious Diseases (DMID) and the Division of Allergy, Immunology and Transplantation (DAIT) support extramural research to control and prevent diseases caused by virtually all infectious agents. This includes basic biomedical research, such as studies of microbial physiology and antigenic structure; immunity; applied research, including the development of diagnostic tests; and clinical trials to evaluate experimental drugs and vaccines. In response to growing concerns about the use of biological agents in acts of terrorism, the further clinical development of new vaccines, therapeutics, adjuvants, diagnostics, and research resources against NIAID Category A, B, and C priority pathogens (see http://www.niaid.nih.gov/biodefense/bandc_priority.htm) is a high priority. In addition, while the long-term public health consequences of Severe Acute Respiratory Syndrome (SARS) are not known, its recent emergence, ease of transmission and disease severity warrant an immediate response from the biomedical research community.
| Federal Grant Title: | Challenge Grants: Biodefense and Sars Product Development |
| Federal Agency Name: | National Institutes of Health |
| Grant Categories: | Health |
| Type of Opportunity: | Discretionary |
| Funding Opportunity Number: | RFA-AI-03-016 |
| Type of Funding: | Cooperative Agreement |
| CFDA Numbers: | 93.85593.856 |
| CFDA Descriptions: | Allergy, Immunology and Transplantation Research 93.856 Microbiology and Infectious Diseases Research |
| Current Application Deadline: | No deadline provided |
| Original Application Deadline: | Jan 13, 2004 |
| Posted Date: | Sep 26, 2003 |
| Creation Date: | Feb 12, 2004 |
| Archive Date: | Feb 12, 2004 |
| Total Program Funding: | |
| Maximum Federal Grant Award: | |
| Minimum Federal Grant Award: | |
| Expected Number of Awards: | |
| Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster